<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01664910</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0265</org_study_id>
    <secondary_id>NCI-2012-02072</secondary_id>
    <secondary_id>2012-0265</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01664910</nct_id>
  </id_info>
  <brief_title>CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies</brief_title>
  <official_title>Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and the best dose of inotuzumab ozogamicin
      when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab
      before donor stem cell transplant in treating patients with lymphoid malignancies. Giving
      chemotherapy drugs, such as fludarabine phosphate and bendamustine hydrochloride, before a
      donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal
      cell and helps stop the patient's immune system from rejecting the donor's stem cells.
      Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and rituximab, may
      help the body's immune system attack the cancer, and may interfere with the ability of tumor
      cells to grow and spread. When the healthy stem cells from a donor are infused into the
      patient they may help the patient's bone marrow make stem cells, red blood cells, white blood
      cells, and platelets. Sometimes the transplanted cell from a donor can make an immune system
      response against the body's normal cells. Giving fludarabine phosphate and bendamustine
      hydrochloride before the transplant together with anti-thymocyte globulin and tacrolimus may
      stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To characterize the safety of anti-cluster of differentiation (CD) 22 immunoconjugate
      inotuzumab ozogamicin (CMC-544), when administered in conjunction with fludarabine
      (fludarabine phosphate), bendamustine (bendamustine hydrochloride), and rituximab as
      non-myeloablative preparative regimen for allogeneic stem cell transplantation for
      CD22-positive lymphoid malignancies.

      SECONDARY OBJECTIVES:

      I. To estimate tumor response. II. To determine overall and event-free survival rates by
      histology subtype.

      OUTLINE: This is a dose-escalation study of inotuzumab ozogamicin.

      Patients receive inotuzumab ozogamicin intravenously (IV) over 1 hour on day -13, and
      fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1
      hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6
      hours on days -6, 1, and 8 and patients with matched unrelated donors (MUD) receive
      anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive
      tacrolimus IV over 24 hours continuously or orally (PO) daily beginning on days -2 to 180
      followed by taper in the absence of graft-versus-host disease (GVHD) and methotrexate IV over
      30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo
      allogeneic bone marrow (BM) or peripheral blood stem cell (PBSC) transplant on day 0.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 29, 2012</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) of inotuzumab ozogamicin</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Defined as the highest dose for which the probability of toxicity is closest to 30%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Defined as grade III or IV renal, hepatic, intestinal, neurologic, pulmonary or cardiac adverse events, as well as graft failure or death at any time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective overall response (complete remission and partial remission)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Estimated with a 95% confidence interval in the dose that is declared the MTD. Logistic regression will be used to assess the association between response and disease and clinical characteristics of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Kaplan-Meier survival curves will be used to estimate OS. Cox proportional hazards regression methodology will be used to assess the association between disease and clinical characteristics and the survival outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Kaplan-Meier survival curves will be used to estimate recurrence-free survival. Cox proportional hazards regression methodology will be used to assess the association between disease and clinical characteristics and the survival outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute and chronic graft versus host disease (GVHD)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The method of Gooley et al will be used to estimate the cumulative incidence of acute and chronic GVHD.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic BM transplant</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or BM transplant</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>Bendamustin Hydrochloride</other_name>
    <other_name>Cytostasan Hydrochloride</other_name>
    <other_name>Levact</other_name>
    <other_name>Ribomustin</other_name>
    <other_name>SyB L-0501</other_name>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inotuzumab Ozogamicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>Besponsa</other_name>
    <other_name>CMC-544</other_name>
    <other_name>Way 207294</other_name>
    <other_name>WAY-207294</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSC transplant</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with B-cell hematological malignancies who are eligible for allogeneic
             transplantation

          -  Patients must have a fully-matched sibling donor or a matched unrelated donor
             identified

          -  Performance score of at least 80% by Karnofsky or 0 to 2 Eastern Cooperative Oncology
             Group (ECOG)

          -  Left ventricular ejection fraction (EF) &gt;= 45% with no uncontrolled arrhythmias or
             symptomatic heart disease

          -  Forced expiratory volume in one second (FEV1) &gt;= 50%

          -  Forced vital capacity (FVC) &gt;= 50%

          -  Corrected diffusion capacity of the lung for carbon monoxide (DLCO) &gt;= 50%

          -  Serum creatinine &lt; 1.6 mg/dL

          -  Serum bilirubin &lt; 2 mg/dL upper limit of normal (unless due to Gilbert's disease;
             patient with this disease should have a right upper quadrant ultrasound evaluation
             before treatment)

          -  Serum glutamate pyruvate transaminase (SGPT) &lt; 2 x upper limit of normal

          -  Men and women of reproductive potential must agree to follow accepted birth control
             methods (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with
             spermicide, condom with spermicide, or abstinence) for the duration of the study

          -  Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential (defined as not post-menopausal for 12 months or no previous surgical
             sterilization) or currently breast-feeding; pregnancy testing is not required for
             post-menopausal or surgically sterilized women

        Exclusion Criteria:

          -  Patient with active central nervous system (CNS) involvement

          -  Known infection with human immunodeficiency virus (HIV), human T-cell lymphotropic
             virus (HTLV)-I, hepatitis B, or hepatitis C

          -  Patients with other malignancies diagnosed within 2 years prior to study registration;
             skin squamous or basal cell carcinoma are exceptions

          -  Active bacterial, viral or fungal infections

          -  History of stroke within 6 months

          -  History of biliary colic attack

          -  A prior autologous transplant within 3 months of study entry or allogeneic stem cell
             transplant

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Patient has received other investigational drugs within 3 weeks before study
             registration

          -  Serious nonmalignant disease which, in the opinion of the investigator would
             compromise protocol objectives

          -  Prior exposure to CMC-544 within past 6 months

          -  Established refractoriness to CMC-544
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa Khouri</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 10, 2012</study_first_submitted>
  <study_first_submitted_qc>August 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2012</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Inotuzumab Ozogamicin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

